Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**EMUAID** is a Speer Laboratories topical first-aid ointment marketed in the United States as an unapproved homeopathic human OTC drug product. Its labeled active ingredient is **Argentum metallicum** at 10x, 20x, and 30x HPUS homeopathic dilutions; the product is intended for temporary relief of symptoms such as minor pain, inflammation, itching, redness, burning, and stinging associated with minor wounds, burns, rashes, insect bites, acne eruptions, eczema eruptions, and minor skin infections. The label describes topical antiseptic, analgesic, and anti-inflammatory purposes, but FDA labeling states that the homeopathic product has not been evaluated by FDA for safety or efficacy and that FDA is not aware of scientific evidence supporting homeopathy as effective. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07b160d3-107c-4c29-a38e-f343e5b3a714))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EMUAID.